跳至主要内容
临床试验/CTRI/2025/11/097613
CTRI/2025/11/097613尚未招募Phase 3 4

Evaluation of Efficacy and Safety of Ayurvedic Formulation in Managing Madhumeha, Glycaemia, and Clinical Outcomes Secondary to Chronic Glycaemia

Dabur India Limited1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年11月30日最近更新:

试验速览

阶段
Phase 3 4
状态
尚未招募
入组人数
60
试验地点
1

研究概览

简要总结

Objective:  Objective of this study is to assess the efficacy and safety of an Ayurvedic Formulation in improving the condition of Madhumeha by managing glycaemia and enhancing clinical outcomes related to chronic glycaemia. This will be an open label, two arm, prospective clinical study to evaluate efficacy and safety study having two dose groups of at least 25 subjects each.  After obtaining ethics committee approval and registering the study on the Clinical Trial Registry of India (CTRI), eligible participants aged 30–70 years as known cases of hyperglycaemia with or without OHAs will be screened and enrolled. There will be four visits per subject. On visit 1, subjects who consent to participate in the study will be screened based on inclusion-exclusion criteria and undergo a Physical & systemic examination. After obtaining ethics committee approval and registering the study on the Clinical Trial Registry of India (CTRI), eligible participants aged 30–70 years as known cases of hyperglycaemia with or without OHAs will be screened and enrolled. There will be four visits per subject. On visit 1, subjects who consent to participate in the study will be screened based on inclusion-exclusion criteria and undergo a Physical & systemic examination. Trial participants will then be allocated to trial treatment for a duration of 4 months active treatment.

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
Participant Blinded

入排标准

年龄范围
30.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • Signed and dated informed consent.
  • Age between 30 years to 70 years (both inclusive) 3) Confirmed cases of hyperglycaemia without any comorbidity/complications with random blood sugar between more than equal to 170 mgperdl to less than equal to 250 mgperdl with or without OHAs. 4) Levels of Hb1Ac above 5.7percent.
  • Confirmed cases of three consecutive high blood sugar levels.

排除标准

  • Patients unwilling to give informed consent.
  • Uncontrolled hyperglycaemia morethan 250 mgperdl with OHA and insulin therapy.
  • Multiple organ failure or ambulatory cases.
  • History of unstable angina, myocardial infarction, cerebrovascular accident, renal/hepatic failure, oncotherapy, high-dose steroids, or severe respiratory disorders.
  • Women with missed menstruation over 3 months, on hormone therapy for pregnancy or known pregnancy cases.

研究者

申办方类型
Other [ayurveda]
责任方
Principal Investigator
主要研究者

Prof Dr Govind Prasad Gupta

Post Graduate Institute of Ayurved Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University Jodhpur

研究点 (1)

Loading locations...

相似试验